Cover Image
市場調查報告書

全球乳癌診斷、藥物技術市場

Breast Cancer Diagnostic and Drug Technologies: Global Markets

出版商 BCC Research 商品編碼 245536
出版日期 內容資訊 英文 154 Pages
訂單完成後即時交付
價格
Back to Top
全球乳癌診斷、藥物技術市場 Breast Cancer Diagnostic and Drug Technologies: Global Markets
出版日期: 2018年05月23日 內容資訊: 英文 154 Pages
簡介

全球乳癌診斷及治療藥市場,預計從2017年的182億美元到2022年達到218億美元,期間中為3.6%的年複合成長率。

本報告提供全球乳癌診斷、治療藥市場相關調查,各國資料,全球乳房X光攝影、切片檢查、搭配診斷IVD、治療藥市場上收益的估計,主要市場動態、趨勢、機會,M&A、新產品開發、策略、R&D活動相關考察,及主要企業簡介等彙整。

第1章 簡介

第2章 摘要、亮點

第3章 市場、技術背景

  • 簡介
  • 乳癌的分類:各類型
    • 原因,發病率,危險因素
    • 症狀
    • 乳癌的分期
    • 流行病學

第4章 乳癌市場動態

  • 市場成長的促進要素
  • 市場成長的阻礙因素
  • 市場機會

第5章 市場分析:各技術

  • 乳癌診斷市場
  • 乳房X光攝影
  • 乳房切片針市場
  • 乳癌預測診斷市場

第6章 市場分析:各類藥物

  • 概要
  • 乳癌的藥物類別
  • 乳癌市場

第7章 市場分析:各地區

  • 乳癌發病率:各地區
  • 全球市場:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲 (MEA)
    • 南美

第8章 法規情形

  • 乳癌診斷、治療的法規上的課題
  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第9章 專利檢討/新開發

  • 專利檢討
  • 搭配診斷

第10章 醫療費償付形勢

  • 簡介
  • 美國
  • 德國
  • 墨西哥
  • 巴西

第11章 開發平台分析

  • 簡介
  • 乳癌治療開發平台:各階段
  • 乳癌治療開發平台:各企業

第12章 競爭情形

  • 主要的乳房X光攝影設備廠商
  • 主要的乳癌治療藥廠商

第13章 企業簡介

附錄:簡稱

關於BCC Research

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HLC106C

Report Highlights

The global breast cancer diagnostic and drug market should reach $21.8 billion by 2022 from $18.2 billion in 2017 at a compound annual growth rate (CAGR) of 3.6% for the period 2017-2022.

Report Includes:

  • 36 data tables and 47 additional tables
  • Country specific data and analysis for United States, Canada, Mexico, UK, France, Germany, Italy, China, India, Japan, and South Korea
  • Estimated revenue of the global mammography, biopsy, companion diagnostic IVD, and therapeutic markets by various segments and subsegments
  • Identification of key market dynamics, trends, and opportunities
  • Insight into mergers and acquisitions, new product developments, strategies, and research-and-development activities
  • Comprehensive profiles of major players in the market, including Abbvie, Inc., Abbott Laboratories, Bristol-Myers Squibb Company, Dako, Eli Lilly and Company, Novartis International AG, and Pfizer, Inc.

Report Scope

This report is an update to Breast Cancer Diagnostics and Therapeutics Market Report-HLC106B.

The objective of the current report is to provide the readers with updated market estimates for the diagnostics and therapeutics market. This report also highlights current and future market potential for breast cancer therapeutics along with a detailed analysis of the competitive environment, pipeline drugs, blockbuster drugs and other diagnostic and therapeutic development.

The report includes breast cancer epidemiology including global and regional prevalence, incidence and mortality rates; regulatory environment for markers and therapeutics along with recent regulatory approvals, current and new technologies, market projections and market share for key market players. Market drivers, trends and potential regional market opportunities for diagnostics and therapeutics are also identified in this report.

The report details currently available diagnostic breast cancer screening tests, breast cancer staging and prognostic technology advancements, predictive diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA approved drugs for treating breast cancer. Screening biomarkers, pipeline analysis, patent analysis and reimbursement scenarios are some additions to the current report.

This report includes market estimates for breast cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics along with market share of therapeutics by drug class (HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors and hormone receptors), geographic market segmentation of the overall market and global market share by company with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for the year 2016, as the base year, 2017 and a forecast for 2022.

Analyst Credentials

Led by Research Head Karthik Arun, the BCC Research staff is composed of expert analysts skilled in conducting primary research, secondary research and data analysis and who have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in microbiology, electrical engineering, business administration, surgery and other subject areas.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Introduction
  • Classification of Breast Cancer by Type
  • Molecular Subtypes of Breast Cancer
    • Causes, Indications and Risk Factors
    • Symptoms
    • Breast Cancer Staging
    • Epidemiology

Chapter 4: Breast Cancer Market Dynamics

  • Market Drivers
    • Increasing Incidence of Breast Cancer Worldwide
    • Focused Research and Development for Novel Drugs
    • High Increase in Healthcare Expenditure and Funding
    • Increasing Breast Cancer Screening Programs
    • Favorable Reimbursement for Screening and Diagnosis
  • Market Restraints
    • Pricing Pressure Experienced by Innovators
    • High Cost Associated with New Drug Development and Clinical Trials
    • Regulatory and Reimbursement Hurdles
  • Market Opportunity
    • Rising Female Population in Asia Pacific
    • Increased Demand for Technology Innovation
    • Technological Advancement in the Drug Sector
    • Emergence of Breast Cancer Predictive Tests
    • Opportunity for Generic Manufacturers to Exploit Patents at the Verge of Expiry
    • Breast Cancer Therapy: Unmet Needs

Chapter 5: Market Breakdown by Technology

  • Breast Cancer Diagnostic Market
  • Mammography
    • Latest Developments
    • Mammography Procedure Volumes
    • Global Mammography Market
    • Limitations of Mammography
  • Breast Biopsy Device Market
    • Introduction
    • Global Breast Biopsy Device Market
  • Breast Cancer Predictive Diagnostic Market
    • Introduction
    • Predictive Diagnostic Tests
    • Global Breast Cancer Companion Diagnostic Test Market

Chapter 6: Market Breakdown by Drug Class

  • Overview
  • Breast Cancers Drug Classes
  • Breast Cancer Market
    • Antimetabolites
    • Tanaxanes
    • Aromatase Inhibitors
    • HER2 Inhibitor
    • Hormone Therapy

Chapter 7: Market Breakdown by Region

  • Breast Cancer Incidence by Region
  • Global Market by Region
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa (MEA)
    • South America

Chapter 8: Regulatory Scenario

  • Breast Cancer Diagnostics and Therapeutics Regulatory Challenges
  • North America
    • Food and Drug Administration (FDA)
  • Europe
  • Asia-Pacific
    • Japan
    • China
  • South America
    • Brazil

Chapter 9: Patent Review/New Developments

  • Patent Review
  • Companion Diagnostics
    • Patent Expiration

Chapter 10: Reimbursement Landscape

  • Introduction
  • United States
    • Mammography Procedure Reimbursement
    • Biopsy Procedure Reimbursement
    • Breast Cancer Drugs Reimbursement
  • Germany
    • Mammography Procedure Reimbursement
    • Biopsy Procedure Reimbursement
    • Breast Cancer Drugs Reimbursement
  • Mexico
  • Brazil

Chapter 11: Pipeline Analysis

  • Introduction
  • Breast Cancer Therapeutics Pipeline by Phases
    • Phase III
    • Phase II
    • Phase I
  • Breast Cancer Therapeutics Pipeline by Company
    • AbbVie, Inc.
    • Array BioPharma, Inc.
    • AstraZeneca
    • Belrose Pharmaceuticals
    • Beta Pharma
    • BioMarin Pharmaceuticals
    • CASI Pharmaceuticals, Inc.
    • Celgene
    • Celldex Therapeutics
    • Celsion
    • Clovis
    • Eli Lilly
    • Novartis
    • Pfizer
    • Puma Biotechnology
    • Roche
    • Syndax Pharmaceuticals
    • Tesaro Inc.

Chapter 12: Competitive Landscape

  • Major Mammography Equipment Market Players
  • Major Breast Cancer Drug Market Players

Chapter 13: Company Profiles

Appendix: Abbreviations

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table: Global Breast Cancer Diagnostic and Drug Market, by Technology, Through 2022 ($ Millions)
    • Table 1: Difference between Normal and Benign Breast Cancer Cells
    • Table 2: New Female Breast Cancer Cases and Deaths in the United States, by Age, 2017 (No./%)
    • Table 3: Histological Types, Frequency of Occurrence and Rate of Survival (%)
    • Table 4: Different Mucinous Carcinoma
    • Table 5: Critical Steps and Genes Involved in Breast Cancer Metastasis
    • Table 6: Characteristics of Molecular Subtypes of Invasive Breast Cancer
    • Table 7: Local-Regional Recurrence, by Molecular Subtype (%)
    • Table 8: Local-Regional Recurrence, by Molecular Subtypes
    • Table 9: Local-Regional Recurrence, by Molecular Subtype
    • Table 10: Global Breast Cancer Incidence, 2016-2021 (Thousands)
    • Table 11: Global Breast Cancer Incidence and Mortality, 2008 (Thousands)
    • Table 12: New Breast Cancer Cases, by Region, 2009 and 2012 (No.)
    • Table 13: New Breast Cancer Cases in the United States, by Gender, 2010-2019
    • Table 14: New Female Breast Cancer Cases and Deaths in the United States, by Age, 2011 (No.)
    • Table 15: Breast Cancer Incidence and Mortality in the United States, 2011 (No.)
    • Table 16: Global Breast Cancer Incidence, by Country, Through 2012 (No.)
    • Table 17: Asia-Pacific Breast Cancer Incidence and 40+ Female Population, Through 2017
    • Table 18: List of Breast Cancer Drugs and Their Patent Exclusivity Period
    • Table 19: Femara Revenue, 2009-2015
    • Table 20: Indicative List of Available Generic Versions of Letrazole
    • Table 21: Global Mammography Market, by Region, Through 2022 ($ Millions)
    • Table 22: Global Mammography Market, by Device Type, Through 2022 ($ Millions)
    • Table 23: Global Breast Cancer Biopsy Device Market, by Region, Through 2022 ($ Millions)
    • Table 24: Indicative List of Available Breast Cancer Prognostic, Diagnostic, Monitoring and Grading Diagnostics Tests, 2017
    • Table 25: Different Classes of Breast Cancer Drugs
    • Table 26: Global Breast Cancer Drugs Market, by Drug Class, Through 2022 ($ Millions)
    • Table 27: Global Aromatase Inhibitor Drugs Market, by Drug Type, Through 2022 ($ Millions)
    • Table 28: Global HER2 Inhibitor Drugs Market, by Drug Type, Through 2022 ($ Millions)
    • Table 29: Global Hormone Receptor Drugs Market, by Drug Type, Through 2022 ($ Millions)
    • Table 30: Global Breast Cancer Therapy Market, by Region, Through 2022 ($ Millions)
    • Table 31: North America Breast Cancer Therapy Market, by Country, Through 2022 ($ Millions)
    • Table 32: European Breast Cancer Therapy Market, by Country, Through 2022 ($ Millions)
    • Table 33: Breast Cancer Incidence, Men and Women (Germany in Number of Persons)
    • Table 34: Asia-Pacific Breast Cancer Therapy Market, by Country, Through 2022 ($ Millions)
    • Table 35: List of FDA-Approved Drugs, 1996-2017
    • Table 36: List of FDA-approved Companion Diagnostics, 2018
    • Table 37: List of Breast Cancer Drugs Approved by the EMA, 1995-2018
    • Table 38: Companion Diagnostics Patent Review, 2015-2017
    • Table 39: Breast Cancer Therapeutics Patent Review, 2010-2018
    • Table 40: Patent Expiration of Breast Cancer Drugs
    • Table 41: United States Mammography Reimbursement, 2017
    • Table 42: United States Biopsy Procedure Reimbursement, 2017
    • Table 43: Medicare Part B: Breast Cancer Drugs Payment Limit, 2018
    • Table 44: Mammography In-Patient Procedure Reimbursement
    • Table 45: In-Patient Biopsy Procedure Codes
    • Table 46: Breast Cancer Drugs Gemzar and Herceptin Reimbursement, Germany, 2017
    • Table 47: Indicative List of Phase III Breast Cancer Therapy Pipeline
    • Table 48: Indicative List of Phase II Breast Cancer Therapy Pipeline
    • Table 49: Indicative List of Phase I Breast Cancer Therapy Pipeline
    • Table 50: AbbVie, Inc.: Pipeline Drugs
    • Table 51: Array BioPharma, Inc.: Pipeline Drugs
    • Table 52: AstraZeneca: Pipeline Drugs
    • Table 53: Belrose Pharmaceuticals: Pipeline Drugs
    • Table 54: Beta Pharma: Pipeline Drugs
    • Table 55: BioMarin Pharmaceuticals: Pipeline Drugs
    • Table 56: CASI Pharmaceuticals, Inc.: Pipeline Drugs
    • Table 57: Celgene: Pipeline Drugs
    • Table 58: Celldex Therapeutics: Pipeline Drugs
    • Table 59: Celsion: Pipeline Drugs
    • Table 60: Clovis: Pipeline Drugs
    • Table 61: Eli Lilly: Pipeline Drugs
    • Table 62: Novartis: Pipeline Drugs
    • Table 63: Pfizer, Inc.: Pipeline Drugs
    • Table 64: Puma Biotechnology: Pipeline Drugs
    • Table 65: Roche: Pipeline Drugs
    • Table 66: Syndax Pharmaceuticals: Pipeline Drugs
    • Table 67: Tesaro, Inc.: Pipeline Drugs
    • Table 68: AbbVie, Inc.: Company Net Revenue, 2014-2017 ($ Billions)
    • Table 69: Abbott Laboratories: Company Net Revenue, 2014-2017 ($ Billions)
    • Table 70: Abbott Laboratories: Marketed Products, 2016
    • Table 71: AstraZeneca Plc.: Company Net Revenue, 2014-2017 ($ Billions)
    • Table 72: AstraZeneca Plc.: Revenue, by Segment, Through 2016 ($ Millions)
    • Table 73: AstraZeneca Plc.: Marketed Products, 2016
    • Table 74: Bristol-Myers Squibb Company: Net Revenue, 2014-2016 ($ Millions)
    • Table 75: Eli Lilly and Company: Net Revenue, 2014-2017 ($ Billions)
    • Table 76: Eli Lilly and Company: Net Revenue, by Segment, 2014-2016 ($ Millions)
    • Table 77: Eli Lilly and Company: Revenue, by Oncology Drugs, 2014-2016 ($ Millions)
    • Table 78: F. Hoffmann-La Roche, Ltd.: Net Revenue, by Segment, Through 2017 ($ Millions)
    • Table 79: Novartis International AG: Net Revenue, by Segment, Through 2017 ($ Millions)
    • Table 80: Pfizer, Inc.: Net Revenue, 2014-2016 ($ Millions)
    • Table 81: Pfizer, Inc.: Oncology Drugs Revenue, 2015-2016 ($ Millions)
    • Table 82: Abbreviations Used in Breast Cancer Diagnostic and Drug Technology

List of Figures

  • Summary Figure: Global Breast Cancer Diagnostic and Drug Market, by Technology, 2016-2022 ($ Millions)
    • Figure 1: Breast Anatomy of Normal and Cancerous Ducts and Lobules
    • Figure 2: Market Share of Invasive and Non-invasive Breast Cancer, United States, 2017 (%)
    • Figure 3: Histopathological Classification of Breast Cancer
    • Figure 4: Non-invasive Breast Cancer Cases in the United States, 2015 (Number of Cases)
    • Figure 5: New Cases of Invasive Breast Cancer in the United States, 2015 (Number of Cases)
    • Figure 6: Invasive Breast Cancers Market Share, by Type (%)
    • Figure 7: Occurrence of Molecular Subtypes (%)
    • Figure 8: Global Burden of Breast Cancer
    • Figure 9: National Cancer Institute Research Funding, 2011-2016 ($ Millions)
    • Figure 10: NCRI Breast Cancer Research Spending, 2010-2017 ($ Millions*)
    • Figure 11: Total Number of Mammography Procedures in the United States, Canada and Mexico, 2010-2015 (Per 1,000,000 Inhabitants)
    • Figure 12: Total Number of Mammography Procedures in Europe, 2010-2015 (Per 1,000,000 Inhabitants)
    • Figure 13: Total Number of Mammography Procedures in Asia-Pacific, 2010-2015 (Per 1,000,000 Inhabitants)
    • Figure 14: Global Mammography Market, 2016-2022 ($ Millions)
    • Figure 15: Global Breast Cancer Companion Diagnostic Market, 2016-2022 ($ Millions)
    • Figure 16: Global Breast Cancer Drugs Market Share, by Drug Class, 2016 (%)
    • Figure 17: Global Aromatase Inhibitor Drugs Market, by Drug Type, 2016-2022 ($ Millions)
    • Figure 18: Global HER2 Inhibitor Drugs Market, by Drug Type, 2016-2022 ($ Millions)
    • Figure 19: Global Hormone Receptor Drugs Market, by Drug Type, 2016-2022 ($ Millions)
    • Figure 20: Global Breast Cancer Incidence, by Region, 2012 (Per 100,000 Persons)
    • Figure 21: Middle East and Africa Breast Cancer Therapy Market, by Country, 2016-2022 ($ Millions)
    • Figure 22: South America Breast Cancer Therapy Market, by Country, 2016-2022 ($ Millions)
    • Figure 23: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
    • Figure 24: Medical Device PMDA Approval Procedure
    • Figure 25: Reimbursement of Drugs in Germany
    • Figure 26: Global Market Share of Mammography Equipment, by Company, 2016* (%)
    • Figure 27: Global Market Share of Breast Cancer Drugs, by Company, 2016 (%)
    • Figure 28: AbbVie, Inc.: Net Revenue, 2013-2016 ($ Billions)
    • Figure 29: AbbVie, Inc.: Lupron Sales, 2014-2016 ($ Millions)
    • Figure 30: Abbott Laboratories: Revenue Share, by Segment, 2016 (%)
    • Figure 31: AstraZeneca Plc.: Revenue, by Drug, 2014-2016 ($ Millions)
    • Figure 32: Bristol-Myers Squibb Company: Revenue Share, by Region, 2016 (%)
    • Figure 33: Bristol-Myers Squibb Company: Revenue Share, by Business Segment, 2016 (%)
    • Figure 34: Eli Lilly and Company: Revenue Share, by Region, 2016 (%)
    • Figure 35: F. Hoffmann-La Roche, Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016 (%)
    • Figure 36: F. Hoffmann-La Roche, Ltd.: Breast Cancer Drugs Revenue, 2014-2017 ($ Millions)
    • Figure 37: F. Hoffmann-La Roche, Ltd.: Breast Cancer Drugs Revenue, by Region, 2016 (%)
    • Figure 38: Novartis International AG: Breast Cancer Drugs Revenue, 2014-2016 ($ Millions)
    • Figure 39: Pfizer, Inc.: Breast Cancer Drugs Revenue, 2015 and 2016 ($ Millions)
    • Figure 40: Aromasin Revenue, 2010-2013 ($ Millions)
    • Figure 41: Sanofi S.A.: Pharmaceuticals Segment Revenue Share, by Therapy, 2017 (%)
    • Figure 42: Sanofi S.A.: Breast Cancer Drug Taxotere Revenue, 2011-2017 ($ Millions)
Back to Top